ORYZON announces U.S. patent grant for vafidemstat in borderline personality disorder (BP... 08/07/2026 Healthcare Rare diseases Innovative drugs Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD. Partners - Oryzon Genomics
World ALS Day | “ALS research is currently going through a particularly promising moment” 21/06/2026 Healthcare Rare diseases Innovative drugs Personalized medicine We interview Alfonso de Egaña Barrenechea, CEO of Molefy Pharma, a company developing AP-2, an innovative molecule... AseBio - MOLEFY PHARMA
Research on the TDP-43 protein opens new therapeutic avenues for ALS 20/06/2026 Biotechnology is driving new strategies to combat ALS, including research on the TDP-43 protein, a key target involved... AseBio
Shilpa Biocare Invests in Gate2Brain to Advance G2B-002, an Innovative Brain Cancer Thera... 16/06/2026 Healthcare Rare diseases Innovative drugs Gate2Brain signs a strategic partnership with Shilpa Biocare, including a €7 million investment for a 30.4% equity stake... Partners - Gate2Brain
Miramoon Pharma Wins Second Prize at ARVO 2026 Eye Pitch Competition 27/05/2026 Healthcare Rare diseases Advanced therapies The startup receives $15,000 award for its innovative MP-004 therapy targeting retinitis pigmentosa. Partners - Miramoon Pharma
U.S. announces pharmaceutical tariffs under Section 232: what it means for biotech compani... 10/04/2026 Healthcare Drug discovery Rare diseases Innovative drugs Industrial biotechnology International At AseBio, we believe this Executive Order creates uncertainty for the European biotechnology sector—especially for... AseBio
AseBio promotes in Brussels the vision of the Spanish biotechnology sector on the Biotech ... 23/03/2026 Healthcare Rare diseases Innovative drugs Advanced therapies EU projects Our Director General, Ion Arocena, participated in the latest meeting of the MEP Interest Group “EU Biotech and Life... AseBio
Sequencing to diagnose earlier: how biotechnology can help short the rare diseases diagnos... 28/02/2026 Healthcare Rare diseases In a context in which most of these pathologies have a genetic origin, tools such as whole genome sequencing (WGS) are... Partners - Illumina
WORLD Orphan Drug Congress USA Boston USA Del 10/06/2026 to 11/06/2026 Access to innovation Rare diseases
AseBio welcomes the European institutions’ decision to move forward with the EU pharmaceut... 17/12/2025 Healthcare Drug discovery Rare diseases Innovative drugs Advanced therapies Antibiotic resistance As this legislation has not been amended for more than two decades, we encourage the Commission to be more ambitious in... AseBio
